(IN BRIEF) Novartis has agreed to acquire SNV4818 from Synnovation Therapeutics, a next-generation PI3Kα inhibitor designed to selectively target mutations in HR+/HER2- breast cancer. The therapy, currently in Phase 1/2 clinical trials, aims to improve treatment tolerability by focusing on … Read the full press release
Posted in Business, Financial, Healthcare, Investment, Pharma & Biotech, Switzerland
Tagged Breast Cancer Treatment, cancer research, clinical trials Phase 1/2, HR positive HER2 negative, Novartis, Novartis Strengthens Breast Cancer Portfolio with Acquisition of Next Generation Selective PI3Kα Therapy, oncology pipeline, pharmaceutical acquisition, PI3Kα inhibitor, PIK3CA mutation, Pikavation Therapeutics, precision medicine, SNV4818, solid tumors, Synnovation Therapeutics, targeted therapy
(IN BRIEF) Accenture has completed its acquisition of UK artificial intelligence company Faculty, expanding its global capabilities in applied AI and enterprise transformation. As part of the integration, Faculty’s CEO and co-founder Dr. Marc Warner will take on the role … Read the full press release
Posted in Artificial Intelligence (AI), Business, Industrial, Infrastructure & Utilities, Investment, Ireland, Management, News, Technology, United Kingdom
Tagged Accenture, Accenture Integrates Faculty’s AI Expertise and Leadership as Dr. Marc Warner Joins Global Management Committee as CTO, Accenture Strengthens Global AI Capabilities with Faculty Acquisition and Names Dr. Marc Warner as CTO, AI acquisition, AI engineers, AI safety, AI strategy, applied AI companies, artificial intelligence, clinical trial optimization, data science, digital transformation, Dr Marc Warner, enterprise AI solutions, enterprise decision intelligence, faculty, Frontier platform, Global Management Committee, Julie Sweet, Manish Sharma, National Health Service, Novartis, technology leadership
(IN BRIEF) Novartis has announced plans to establish a 46,000-square-foot radioligand therapy manufacturing facility in Denton, Texas, with operations expected to begin in 2028. The new site will expand the company’s U.S. manufacturing network and support growing demand for targeted … Read the full press release
Posted in Business, Healthcare, Pharma & Biotech, Switzerland
Tagged advanced manufacturing, bioengineering jobs, cancer treatment manufacturing, Dallas Fort Worth biotech, Denton Texas, Greg Abbott, Novartis, Novartis Expands Radioligand Therapy Network with New Manufacturing Site in Denton Texas, Novartis Strengthens US Radioligand Therapy Production with Planned Texas Manufacturing Investment, nuclear medicine, oncology pipeline, pharmaceutical manufacturing, radioligand therapy RLT, radiopharmaceuticals, targeted radiation therapy, US investment program, Vas Narasimhan
(IN BRIEF) Novartis announced positive Phase III results from the RemIND trial showing that the oral BTK inhibitor remibrutinib achieved significantly higher complete response rates than placebo in three major forms of chronic inducible urticaria. The treatment demonstrated good tolerability … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged Angelika Jahreis, autoimmune and inflammatory diseases, BTK inhibitor, chronic inducible urticaria, chronic urticaria treatment, CIndU, dermatology innovation, FDA application, global clinical trials, histamine pathway, immunology research, Novartis, Novartis Advances Immunology Pipeline with Promising Late Stage Outcomes for Oral BTK Inhibitor in Rarely Addressed Skin Disorder, Phase III study, regulatory submission, remibrutinib, RemIND trial, Rhapsido, targeted therapy development
(IN BRIEF) Novartis has reported final Phase III ALIGN study results showing that Vanrafia (atrasentan) slowed kidney function decline in adults with IgA nephropathy compared with placebo. At Week 136, the therapy demonstrated a 2.39 ml/min/1.73m² difference in eGFR change … Read the full press release
Posted in Business, Healthcare, Pharma & Biotech, Switzerland
Tagged accelerated approval United States China, ALIGN study, atrasentan, EGFR, endothelin A receptor antagonist, Fabhalta, Final ALIGN Data Support Vanrafia as Potential Foundational Therapy to Slow Kidney Function Decline in IgAN, IgA nephropathy, IgAN, iptacopan, kidney disease, Novartis, Novartis Advances IgA Nephropathy Portfolio with Positive Long-Term Phase III Results for Vanrafia, phase III clinical trial, proteinuria, RAS inhibitors, renal function decline, Ruchira Glaser, SGLT2 inhibitors, Vanrafia, zigakibart
(IN BRIEF) Novartis announced new MONALEESA pooled analysis results showing that 25% of HR+/HER2- metastatic breast cancer patients treated first-line with Kisqali plus endocrine therapy remained progression-free for four or more years, with a median PFS of 6.8 years. Durable … Read the full press release
Posted in Business, Healthcare, Pharma & Biotech, Switzerland
Tagged biomarkers, CDK4/6 inhibitor, ctDNA, early breast cancer, endocrine partner therapy, endocrine therapy, ESMO MCBS rating, global oncology research, HR+/HER2- breast cancer, Kisqali demonstrates sustained outcomes across trials as Novartis highlights long-term control and recurrence reduction, Kisqali®, long-term progression-free survival, Luminal A subtype, Mark Rutstein, metastatic breast cancer, MONALEESA trials, NATALEE trial, NCCN Category 1, Novartis, OS benefit, Pedram Razavi, precision oncology, ribociclib, SAN ANTONIO Breast Cancer Symposium SABCS
(IN BRIEF) Novartis will present new data from 27 abstracts at the 2025 American College of Rheumatology (ACR) Convergence, featuring late-breaking Phase III results from the NEPTUNUS-1 and NEPTUNUS-2 trials of ianalumab in Sjögren’s disease, which could become the first … Read the full press release
Posted in Business, Healthcare, Investment, Pharma & Biotech, Switzerland
Tagged ACR 2025, allergy, Angelika Jahreis, autoimmune diseases, Basel, biologics, biomarker research, CAR-T therapy, Cosentyx, Dermatology, EXPLORE44, Fortitude, HARBOR trial, ianalumab, immunology, NEPTUNUS trials, NEPTUNUS-1, NEPTUNUS-2, Novartis, Novartis Highlights Strong Immunology Pipeline with Positive Phase III Sjögren’s Results and CAR-T Data in Lupus at ACR 2025, Phase III data, psoriatic arthritis, rapcabtagene autoleucel, rheumatology, secukinumab, Sjögren’s disease, small molecules, systemic lupus erythematosus, YTB323
(IN BRIEF) Novartis announced a definitive agreement to acquire Avidity Biosciences for USD 12 billion in cash, in a move that strengthens its neuroscience franchise and accelerates its xRNA therapeutic strategy. The acquisition brings Avidity’s late-stage programs in myotonic dystrophy … Read the full press release
Posted in Business, Healthcare, Investment, Pharma & Biotech, Switzerland
Tagged acquisition, Antibody Oligonucleotide Conjugates, AOCs, Avidity Biosciences, Basel, biopharma, biopharmaceutical innovation, biotechnology, clinical research, DM1, DMD, drug development, Duchenne muscular dystrophy, EXPLORE44 trial, facioscapulohumeral muscular dystrophy, FORTITUDE trial, FSHD, genetic medicine, HARBOR trial, muscle-directed therapy, myotonic dystrophy type 1, neuromuscular diseases, Novartis, Novartis Strengthens Neuroscience Franchise with Acquisition of Avidity Biosciences and Its Muscle-Directed RNA Platform, RNA delivery, RNA therapeutics, San Diego, SpinCo, Vas Narasimhan, xRNA strategy
(IN BRIEF) The Institute of Cancer Research and NEOsphere Biotechnologies have announced a new collaboration to accelerate the discovery of molecular glue degrader drugs, an innovative approach in targeted cancer therapy. The partnership will integrate ICR’s proprietary molecular glue library … Read the full press release
Posted in Business, Education, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Academic–industry partnership to accelerate rational design of molecular glue degrader drugs for cancer treatment, artificial intelligence, Cancer Drug Discovery, cancer research innovation, Centre for Protein Degradation, computational drug design, E3 ligases, Henrik Daub, high-throughput proteomics, ICR, ICR and NEOsphere Biotechnologies join forces to pioneer systematic discovery of molecular glue degrader therapies, Institute of Cancer Research, Institute of Cancer Research and NEOsphere Biotechnologies partner to advance molecular glue degrader drug discovery, Jonathan Beech, Machine Learning, MGDs, molecular glue degraders, molecular glue library, Monte Rosa Therapeutics, Nature Communications, NEOsphere Biotechnologies, Novartis, proteomics, St Jude Children’s Research Hospital, targeted protein degradation, Zoran Rankovic
(IN BRIEF) Novartis, through its wholly owned subsidiary Torino Merger Sub Inc., has launched a tender offer to acquire all outstanding shares of Tourmaline Bio, Inc. at USD 48 per share in cash. The offer commenced September 29, 2025, and … Read the full press release
Posted in Business, Healthcare, Investment, Pharma & Biotech, Switzerland
Tagged acquisition, biopharma acquisition, Computershare Trust Company, Hart-Scott-Rodino Act, Innisfree M&A, M&A, Merger Agreement, Novartis, Novartis Commences Tender Offer to Acquire Tourmaline Bio for USD 48 Per Share, Novartis Moves Forward with Acquisition of Tourmaline Bio Through Tender Offer, Novartis Pursues Strategic Acquisition of Tourmaline Bio with USD 48 Per Share Tender, Schedule 14D-9, Schedule TO, SEC filing, shareholder offer, tender offer, Torino Merger Sub, Tourmaline Bio, USD 48 per share
(IN BRIEF) Novartis will launch a direct-to-patient (DTP) platform in the US on November 1, 2025, starting with Cosentyx, which will be offered at a 55% discount off list price for cash-paying patients. Cosentyx, a biologic approved for multiple immune-mediated … Read the full press release
Posted in Healthcare, Marketing, Pharma & Biotech, Switzerland
Tagged biologics, Cosentyx, direct-to-employer model, direct-to-patient platform, discount medicines, drug affordability, DTP, hidradenitis suppurativa, immune-mediated inflammatory diseases, New Direct-to-Patient Platform from Novartis Aims to Reduce Barriers and Improve Affordability, Novartis, Novartis Launches Direct-to-Patient Platform in US with Discounted Access to Cosentyx, Novartis to Provide Patients Direct Access to Lower-Priced Cosentyx Starting November 2025, NPAF, patient access, patient assistance, psoriasis, psoriatic arthritis, secukinumab, specialty medicines, US healthcare, Victor Bultó
(IN BRIEF) Novartis will present 19 abstracts at the 2025 European Society of Cardiology (ESC) Congress in Madrid, showcasing new findings across its cardiovascular portfolio. Key highlights include two VictORION studies on Leqvio’s impact on quality of life and its … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, Media, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged abelacimab, atrial fibrillation, AZALEA-TIMI 71, cardiovascular disease, cardiovascular pipeline therapies, Chagas disease, Entresto, ESC Congress 2025, European Society of Cardiology, heart failure, inclisiran, Leqvio, lipoprotein apheresis, lipoprotein(a), Lp(a)FRONTIERS APHERESIS trial, Novartis, PARACHUTE-HF trial, pelacarsen, Sacubitril Valsartan, VictORION studies, xRNA platform
(IN BRIEF) Novartis has reported landmark Phase III results showing that ianalumab significantly reduced disease activity in patients with Sjögren’s disease, meeting primary endpoints in both the NEPTUNUS-1 and NEPTUNUS-2 trials. The treatment, which combines B-cell depletion and BAFF-R inhibition, … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged autoimmune disease, B cell depletion, BAFF-R inhibition, biopharmaceuticals, clinical trial results, ESSDAI, Fast Track Designation, ianalumab, immunology research, MorphoSys AG, NEPTUNUS-1, NEPTUNUS-2, Novartis, Shreeram Aradhye, Sjögren’s disease, systemic autoimmune disorder, targeted therapy, US FDA, VAY736
(IN BRIEF) Novartis has appointed Mukul Mehta as CFO and Executive Committee member effective March 16, 2026. He will replace long‑time CFO Harry Kirsch, who retires on March 15, 2026, after 22 years at the company. Kirsch oversaw major strategic … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged 22-year career, Alcon spinoff, appointment, business planning and analysis, CFO appointment, digital finance, ECN, Executive Committee, focused medicines strategy, global finance leadership, GSK divestiture, Harry Kirsch, INSEAD, Jamnalal Bajaj Institute of Management Studies, leadership, March 16 2026, Mukul Mehta, Novartis, retirement, Roche divestiture, Sandoz spinoff, TAX, Vas Narasimhan
(IN BRIEF) Novartis has announced that its Phase III PSMAddition trial of Pluvicto™ in combination with standard of care (SoC) has met its primary endpoint, showing a significant benefit in radiographic progression-free survival (rPFS) and a positive trend in overall … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged androgen receptor pathway inhibitors, cancer research, clinical trials, FDA approval, FDA regulatory review, metastatic castration-resistant prostate cancer, metastatic hormone-sensitive prostate cancer, mHSPC, Novartis, Novartis oncology, overall survival, Phase III PSMAddition, Pluvicto, progression-free survival, prostate cancer, prostate cancer treatment, PSMA-positive, radioligand therapy, treatment options
(IN BRIEF) Novartis has presented new data from the Phase III NATALEE trial at ASCO 2025, showcasing Kisqali’s ability to reduce the risk of recurrence in pre-menopausal patients with high-risk early breast cancer. The data reveals a 33% reduction in … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged adjuvant treatment, ASCO 2025, Black patients, Breast Cancer Treatment, CDK4/6 inhibitors, DDFS, disparities in healthcare, early breast cancer, EBC, endocrine therapy, HR+/HER2-, invasive disease-free survival, Kisqali®, metastatic breast cancer, Novartis, Phase III NATALEE, post-menopausal, pre-menopausal, recurrence-free survival, RFS, ribociclib, Risk Reduction, survival benefit
(IN BRIEF) The Vienna Stock Exchange has expanded its global market offering by allowing the trading of all stocks in the Swiss Market Index (SMI), which includes leading companies like Nestlé, Novartis, Roche, and UBS. This follows the Swiss Federal … Read the full press release
(IN BRIEF) Syngenta has acquired Novartis’ natural products and genetic strains assets to enhance its biologicals research capabilities and support the agricultural sector’s transition to sustainability. This acquisition complements the opening of a state-of-the-art biologicals production facility in South Carolina … Read the full press release
Posted in Agriculture, Chemicals, Industrial, Investment, Switzerland
Tagged AI, analytics, Basel, bio-insecticides, biocontrols, bioengineering, biologicals, biologicals production facility, Biomolecular Chemistry team, biostimulants, Camilla Corsi, crop protection, data science, downstream processing, fermentation, genetic strains, Ginkgo Bioworks, Intrinsyx Bio, Jonathan Brown, Latin America, Lavie Bio, Lithos Crop Protect, natural products, North America, Novartis, Novartis Natural Products, nutrient efficiency, nutrient use efficiency, Orangeburg, pheromone solutions, Provivi, Regenerative Agriculture, research and development, Seedcare, soil health, South Carolina, Sustainability Priorities, sustainable farming practices, Switzerland, Syngenta, TraitSeq, Valagro
(IN BRIEF) Novartis has announced its acquisition of Anthos Therapeutics, a Boston-based biopharmaceutical company focused on developing abelacimab, an investigational monoclonal antibody currently in Phase 3 trials for preventing stroke and systemic embolism in patients with atrial fibrillation. This acquisition … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged abelacimab, acquisition, Anthos Therapeutics, anticoagulation, atrial fibrillation, biopharmaceutical company, Blackstone Life Sciences, bleeding reduction, Boston, cancer-associated thrombosis, cardiovascular, cardiovascular therapeutic area, clinical-stage, David Soergel, Factor XI inhibition, Fast Track Designation, FDA, medical research, Novartis, partnership, Phase 3 trials, regulatory milestones, Shreeram Aradhye, stroke prevention, systemic embolism, therapeutic focus, thrombosis
(IN BRIEF) The University of St.Gallen and ETH Zurich have partnered to establish the “ETH-HSG Manufacturing Alliance,” aimed at boosting the competitiveness of Swiss industry and nurturing young talent. The alliance is supported by 13 leading industrial partners, including Roche, … Read the full press release
Posted in Business, Education, Financial, Industrial, Investment, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged artificial intelligence, artnership, Circle of Scholars, doctoral students, Endress+Hauser Flowtec, ETH Zurich, ETH-HSG Manufacturing Alliance, Givaudan, Johnson & Johnson Innovative Medicine, Leila Schwery, Lindt & Sprüngli, manufacturing innovation, Nestlé, Novartis, Operational Excellence, Peter Hagmann, Roche, Schindler, Schneider Electric, SFS Group, SHL Medical, sustainable business practices, Swiss industry, Swiss Manufacturing Survey 2024, Takeda, talent development, University of St.Gallen, VAT Group
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?